The invention relates to an ultrasound contrast agent (UCA) comprising an outer shell and a gas core. The gas core is filled with oxygen, and the outer shell comprises a first surfactant and a second surfactant. The invention also relates to a method of making an oxygen-filled UCA and delivering oxygen to a local area of a subject's body. The method comprises injecting a composition comprising an oxygen-filled UCA of the invention into the subject's body; directing ultrasound radiation to the local area in an intensity sufficient to rupture the UCA.

The present invention relates to: a pharmaceutical composition for treating cancer containing, as an active ingredient, a metal lactate salt, which can be dissociated, in cancer cells, into lactate capable of effectively inhibiting actions such as proliferation, invasion, and metastasis of cancer cells by disturbing the metabolic processes of cancer cells; a pharmaceutical composition for inhibiting cancer metastasis; a food composition for alleviating cancer; and a method for treating cancer and a method for inhibiting cancer matastasis, both methods comprising a step of administering the lactate metal salt. The metal lactate salts of the present invention as disclosed inhibit the growth of cancer cells and induce the death of cancer cells by disturbing the metabolic processes in the main energy production pathways of cancer, and inhibit the expression of factors inducing resistance against radiation exposure, while having no side effects. Therefore, the lactate metal salt can be widely utilized in a more effective anti-cancer therapy.

The disclosure relates to methods for treating tumors. In particular, the disclosure relates to a method of treating a tumor by ionizing radiations in a subject in need thereof, said method comprising the steps of: (i) injecting a first therapeutically effective amount of high-Z element containing nanoparticles as radiosensitizing agents in said subject in need thereof within a period between 2 and 7 days prior to the first irradiation of the tumor, (ii) injecting a second therapeutically effective amount of the same or different high-Z element containing nanoparticles within a period between 1 hour to 12 hours prior to the first irradiation of the tumor, and, (iii) irradiating the tumor of said subject with a therapeutically efficient dose of radiations;
wherein said high-Z element containing nanoparticles are nanoparticles containing an element with an atomic Z number higher than 40 and said nanoparticles have a mean hydrodynamic diameter below 10 nm.

A boron neutron capture therapy system includes a neutron capture therapy device, a photon emission detection device and a treatment bed. The photon emission detection device includes a detecting portion surrounding the periphery of the treatment bed and detecting gamma rays generated after irradiating a boron-containing drug with neutrons; the detecting portion includes a first detecting portion and a second detecting portion moving away from or close to the first detecting portion so that the detecting portion forms a ring with the radius being increased or decreased; and the ring surrounds the treatment bed. The photon emission detection device for use in the boron neutron capture therapy system can change the radius of the ring, surrounding an irradiated object, of the detecting portion according to the actual condition in the boron neutron capture therapy so as to improve the detection precision of the photon emission detection device.

Methods for the treatment of cancers, in particular deep-tissue cancers, using x-ray induced near-infrared photoimmunotherapy are described herein.

The present disclosure lies in the field of medical radiotherapy and relates to an applicator for a medical radiotherapy device, an applicator system for a medical radiotherapy device and a method for using an applicator or an applicator system. The applicator includes an applicator head and an applicator body. The applicator head and the applicator body are embodied such that the applicator head can be assembled on, and disassembled from, the applicator body, in each case without damage.

A virtual 511 KeV attenuation map is generated from CT data. Spectral or multiple energy CT is used to more accurately extrapolate the 511 KeV attenuation map. Since spectral or multiple energy CT may allow for material decomposition and/or due to additional information in the form of measurements at different energies, the modeling used to generate the 511 KeV attenuation map may better account for all materials including high density material. The extrapolated 511 KeV attenuation map may more likely represent actual attenuation at 511 KeV without requiring extra scanning using a 511 KeV source external to the patient. The virtual 511 KeV attenuation map (e.g., CT data at 511 KeV) may provide more accurate PET image reconstruction.

The present disclosure provides antibody drug conjugates comprising STING modulators. Also provided are compositions comprising the antibody drug conjugates. The compounds and compositions are useful for stimulating an immune response in a subject in need thereof.

The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.

A method and a system for producing a change in a medium disposed in an artificial container. The method places in a vicinity of the medium at least one of a plasmonics agent and an energy modulation agent. The method applies an initiation energy through the artificial container to the medium. The initiation energy interacts with the plasmonics agent or the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the plasmonics agent or the energy modulation agent.